Clinical Trials Logo

Hypercholesterolemia, Familial clinical trials

View clinical trials related to Hypercholesterolemia, Familial.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04656028 Recruiting - Clinical trials for Medication Adherence

Genetic Testing and Motivational Counseling for FH

GENMOTIV-FH
Start date: June 15, 2020
Phase: N/A
Study type: Interventional

To date, there are highly effective lipid-lowering drugs, the combination of which makes it possible to achieve the target level of LDL-C in most patients with familial hypercholesterolemia (FH). However, the effectiveness of treatment of FH patients strongly depends on adherence to lipid-lowering therapy and to the healthy lifestyle, as well as the detection of the disease and the therapy prescription as early as possible, better in childhood. The aim of the study is to assess the impact of genetic testing and motivational counseling on the effectiveness of treatment and cascade screening in patients with FH.

NCT ID: NCT04313270 Recruiting - Clinical trials for Hypercholesterolemia, Familial

Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®

Start date: December 1, 2017
Phase:
Study type: Observational

Protein convertase subtilisin kexin type 9 (PCSK-9) inhibitors demonstrated efficacy in cholesterol reduction and in the prevention of cardiovascular events. The investigators will evaluate changes in lipid profile, oxidation markers and subclinical atherosclerosis in patients with familial hypercholesterolemia (FH) during 12 weeks of treatment with a PCSK-9 inhibitor, Evolocumab®.

NCT ID: NCT04073797 Recruiting - Atherosclerosis Clinical Trials

PET Imaging of Inflammation and Lipid Lowering Study

PIILL
Start date: March 20, 2023
Phase: N/A
Study type: Interventional

While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a glucose analog, its signal in the vasculature lacks inflammatory cell-specificity. Moreover, high background 18F-FDG signals from the myocardium often preclude coronary artery imaging, despite attempts to suppress myocardial tracer uptake by dietary manipulation. These limitations of 18F-FDG for measuring changes in vascular inflammation arising from drug intervention highlight important unmet needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.

NCT ID: NCT03989167 Recruiting - Clinical trials for Hypercholesterolemia, Familial

Clinical Decision Support for Familial Hypercholesterolemia

CDS-FH
Start date: December 6, 2022
Phase: N/A
Study type: Interventional

A cluster randomized study in the primary care setting to evaluate a computer-based clinical decision support system to aid in the identification and management of patients with FH. The primary outcome of the study is the number of patients diagnosed with FH at thirty months after study initiation.